医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BEIJING

INJEX Pharma AG is pleased to announce that yesterday its wholly owned subsidiary INJEX Pharma GmbH has successfully registered the INJEX30 needle free injection system with the Chinese State Food and Drug Administration (SFDA), supported by its exclusive distributor Hangzhou Hema Medical Equipment Co. Ltd. The SFDA is responsible for regulating the market access of medical devices in the People’s Republic of China. The arduous approval process took more than 1.5 years and has required a detailed documentation.

The registration is a significant milestone in the Company’s efforts to expand its offerings in key markets. One area of application is the use of insulin for persons with diabetes. According to figures in the recent Diabetes Atlas (5th edition, 2012) published by the International Diabetes Federation, about one fourth of the 371 million people with diabetes live in China. Hangzhou Hema Medical Equipment can immediately start marketing the INJEX30 system.

For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com.

INJEX Pharma AG:

INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the medical technology segment and in the cosmetics and beauty markets. The Group’s core business areas are the needle-free INJEX30 system and the product line SHIREEN in the beauty market. The main markets of the Group are North America, China, India, Russia and Europe.